Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 3, 2004, Pages 765-781

  Vassilakopoulos, Theodoros P ^a   Angelopoulou, Maria K ^a   Siakantaris, Marina P ^a   Kontopidou, Flora N ^a   Dimopoulou, Maria N ^a   Kokoris, Styliani I ^a   Kyrtsonis, Marie Christine ^a   Tsaftaridis, Panayiotis ^a   Karkantaris, Christos ^a   Anargyrou, Konstantinos ^a   Boutsis, Dimitrios E ^a   Variamis, Eleni ^a   Michalopoulos, Thymios ^b   Boussiotis, Vassiliki A ^a   Panayiotidis, Panayiotis ^a   Papavassiliou, Constantinos ^b   Pangalis, Gerassimos A ^a,c  

^a UNIVERSITY OF ATHENS   (Greece)

^b HYGEIA HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

ABVD; Early stage; Hodgkin's lymphoma; Radiotherapy

Indexed keywords

DOSIMETRY; IRRADIATION; PATIENT TREATMENT; RADIOTHERAPY; TUMORS;

FAILURE FREE SURVIVAL (FFS); LYMPHOMA; PARTIAL REMISSION;

CHEMOTHERAPY;

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; DATA ANALYSIS; FEMALE; HODGKIN DISEASE; HUMAN; LEUKOCYTOSIS; LOW ENERGY RADIATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RELAPSE; SALVAGE THERAPY; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; EPIRUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PREDNISONE; PROCARBAZINE; PROGNOSIS; RADIOTHERAPY DOSAGE; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 2942618392     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.11.029     Document Type: Article

References (92)

1. Mauch P.M. Controversies in the management of early stage Hodgkin's disease. Blood. 83:1994;318-329
2. Ng A.K., Weeks J.C., Mauch P.M., et al. Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease. J Clin Oncol. 17:1999;3577-3585
3. Hoppe R.T., Coleman C.N., Cox R.S., et al. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy The Stanford experience. Blood. 59:1982;455-465
4. Hellman S., Mauch P. Role of radiation therapy in the treatment of Hodgkin's disease. Cancer Treat Rep. 66:1982;915-923
5. Cornbleet M.A., Vitolo U., Ultmann J.E., et al. Pathologic stages IA and IIA Hodgkin's disease Results of treatment with radiotherapy alone (1968-1980). J Clin Oncol. 3:1985;758-768
6. Carde P., Burgers J.M., Henry-Amar M., et al. Clinical stages I and II Hodgkin's disease A specifically tailored therapy according to prognostic factors. J Clin Oncol. 6:1988;239-252
7. Mauch P., Tarbell N., Weinstein H., et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol. 6:1988;1576-1583
8. Leslie N.T., Mauch P.M., Hellman S. Stage IA to IIB supradiaphragmatic Hodgkin's disease Long-term survival and relapse frequency. Cancer. 55:1985;2072-2078
9. Meeker W.R., Richardson J.D., West W.O., et al. Critical evaluation of laparotomy and splenectomy in Hodgkin's disease. Arch Surg. 105:1972;222-229
10. Mauch P.M., Somers R. Controversies in the use of diagnostic staging laparotomy and splenectomy in the management of Hodgkin's disease. Ann Oncol. 4:1992;41-43
11. Ng A.K., Weeks J.C., Mauch P.M., et al. Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease A decision analysis. J Clin Oncol. 17:1999;241-252
12. Brogadir S., Fialk M., Coleman M., et al. Morbidity of staging laparotomy in Hodgkin's disease. Am J Med. 65:1978;429-453
13. Kinzie J.J., Hanks G.E., MacLean C.J., et al. Patterns of care study Hodgkin's disease relapse rates and adequacy of portals. Cancer. 52:1983;2223-2226
14. Koziner B., Myers J., Cirrincione C., et al. Treatment of stages I and II Hodgkin's disease with three different therapeutic modalities. Am J Med. 80:1986;1067-1078
15. Longo D.L., Glatstein E., Duffey P.L., et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease Seven-year results of a prospective randomized trial. J Clin Oncol. 9:1986;906-917
16. Wirth A., Chao M., Corry J., et al. Mantle irradiation alone for clinical stage I-II Hodgkin's disease Long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol. 17:1999;230-240
17. Lund M.B., Kongerud J., Nome O., et al. Lung function impairment in long-term survivors of Hodgkin's disease. Ann Oncol. 6:1995;495-501
18. Hancock S.L., Tucker M.A., Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 270:1993;1949-1955
19. Ng A.K., Bernardo M.P., Weller E., et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 20:2002;2101-2108
20. van Leeuwen F.E., Klokman W.J., Hagenbeek A., et al. Second cancer risk following Hodgkin's disease A 20-year follow-up study. J Clin Oncol. 12:1994;312-325
21. Tucker M.A., Coleman C.N., Cox R.S., et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 318:1988;76-81
22. Mauch P.M., Kalish L.A., Marcus K.C., et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease Long-term analysis of risk factors and outcome. Blood. 87:1996;3625-3632
23. Henry-Amar M. International Database on Hodgkin's Disease (IDHD). Second cancer after the treatment for Hodgkin's disease A report from the International Database on Hodgkin's disease. Ann Oncol. 3:(Suppl. 4):1992;S117-S128
24. Swerdlow A.J., Douglas A.J., Vaughan Hudson G., et al. Risk of second primary cancers after Hodgkin's disease by type of treatment Analysis of 2846 patients in the British National Lymphoma investigation. BMJ. 304:1992;1137-1143
25. Carde P., Hagenbeek A., Hayat M., et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early stage Hodgkin's disease The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 11:1993;2258-2272
26. Anderson H., Crowther D., Deakin D.P., et al. A randomized study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease 10-year follow-up. Ann Oncol. 2:(Suppl. 2):1991;49-54
27. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 20012;19:4238-4244
28. Sieber M., Franklin J., Tesch H., et al. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease Results of the German Hodgkin's Lymphoma Study Group (GHSG) trial HD7. Blood. 100:2002;93a. [Abstract]
29. Horning S.J., Hoppe R.T., Mason J., et al. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease Subtotal lymphoid irradiation vs vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol. 15:1997;1736-1744
30. Noordijk E.M., Carde P., Mandard A.M., et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. Ann Oncol. 5:(Suppl. 2):1994;107-112
31. Specht L., Gray R.G., Clarke M.J., et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease A meta-analysis of 23 randomized trials involving 3, 888 patients. J Clin Oncol. 16:1998;830-843
32. Prosnitz L.R. Reducing treatment-related morbidity and mortality in early-stage Hodgkin's disease and why the recent Southwest Oncology Group trial is not the way to go. J Clin Oncol. 20:2002;2225-2228
33. Kreuser E.D., Xerus N., Hetzel W.D., et al. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy of Hodgkin's disease. J Cancer Res Clin Oncol. 134:1987;260-266
34. Vassilakopoulos T.P., Angelopoulou M.K., Kontopidou F.N., et al. Pure infradiaphragmatic Hodgkin's disease Analysis of twenty five cases and review of the literature. Haema. 2:1999;90-100
35. Angelopoulou M.K., Vassilakopoulos T.P., Siakantaris M.P., et al. EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease. Leuk Lymphoma. 37:2000;131-143
36. Carbone P.P., Kaplan H.S., Musshoff K., et al. Report of the Committee on Hodgkin's disease staging classification. Cancer Res. 31:1971;1860-1861
37. Mauch P., Goodman R., Hellman S. The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer. 42:1978;1039-1045
38. Ifrah N., Hunault M., Jais J.P., et al. Infradiaphragmatic Hodgkin's disease Long term results of combined modality therapy. Leuk Lymphoma. 21:1996;79-84
39. Vassilakopoulos T.P., Angelopoulou M.K., Siakantaris M.P., et al. Prognostic factors in advanced stage Hodgkin's lymphoma The significance of the number of involved anatomic sites. Eur J Haematol. 67:2001;279-288
40. 2-microglobulin in patients with Hodgkin's lymphoma. Haematologica. 87:2002;701-708
41. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med. 339:1998;1506-1514
42. Wiedenmann S., Schiller P., Paulus U., et al. Treatment of early and intermediate stage Hodgkin's lymphoma in the German Hodgkin's Lymphoma Study Group. Ann Oncol. 13:(Suppl. 1):2002;84-85
43. Canellos G.P., Petroni G.R., Barcos M., et al. Etoposide, vinblastine, and doxorubicin An active regimen for the treatment of Hodgkin's disease in relapse following MOPP. J Clin Oncol. 13:1995;2005-2011
44. Longo D.L., Young R.C., Wesley M., et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 4:1986;1295-1306
45. Bonadonna G., Zucali R., Monfardini S., et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 36:1975;252-259
46. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481
47. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170
48. Cox D.R. Regression models and life tables. J R Stat Soc B. 34:1972;187-220
49. Andrieu J.M., Montagnon B., Asselain B., et al. Chemotherapy-radiotherapy association in Hodgkin's disease, clinical stages IA, II2A Results of a prospective clinical trial with 166 patients. Cancer. 46:1980;2126-2130
50. Zittoun R., Audebert A., Hoerni B., et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol. 3:1985;207-214
51. Colonna P., Jais J.P., Desablens B., et al. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy Ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol. 14:1996;1928-1935
52. Santoro A., Bonfante V., Viviani S., et al. Subtotal nodal (STNI) vs. involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin's disease (HD). Proc Am Soc Clin Oncol. 15:1996;415. [Abstract]
53. Brusamolino E., Lunghi F., Orlandi E., et al. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radiotherapy Analysis of efficacy and long-term toxicity. Haematologica. 85:2000;1032-1039
54. Gobbi P.G., Pieresca C., Frassoldati A., et al. Vinblastine, bleomycin and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients The Gruppo Italiano per lo Studio dei Linfomi experience. J Clin Oncol. 14:1996;527-533
55. Horning S.J., Hoppe R.T., Hancock S.L., et al. Vinblastine, bleomycin and methotrexate An effective adjuvant in favorable Hodgkin's disease. J Clin Oncol. 6:1988;1822-1831
56. Bates N.P., Williams M.V., Bessell E.M., et al. Efficacy and toxicity of vinblastine, bleomycin and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease A British National Lymphoma Investigation pilot study. J Clin Oncol. 12:1994;288-296
57. Hagemeister F.B., Fuller L., McLaughlin P., et al. NOVP and radiotherapy for early-staged Hodgkin's disease An interim analysis. Ann Oncol. 3:(Suppl 4):1992;87-90
58. Brizel D.M., Winer E.P., Prosnitz L.R., et al. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys. 19:1990;535-542
59. Diehl V., Loeffler M., Pfreundschuh M., et al. Further chemotherapy versus low dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease. Ann Oncol. 6:1995;901-910
60. Fabian C.J., Mansfield C.M., Dahlberg S., et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease A Southwest Oncology Group randomized study. Ann Intern Med. 120:1993;903-912
61. Prosnitz L.R., Farber L.R., Kapp D.S., et al. Combined modality therapy for advanced Hodgkin's disease 15-year follow-up data. J Clin Oncol. 6:1988;603-612
62. Sears J.D., Greven K.M., Ferree C.R., et al. Definitive irradiation in the treatment of Hodgkin's disease Analysis of outcome, prognostic factors, and long term complications. Cancer. 79:1997;145-151
63. Loeffler M., Diehl V., Pfreundschuh M., et al. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol. 15:1997;2275-2287
64. Chronowski G.M., Wilder R.B., Tucker S.L., et al. Analysis of infield control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys. 55:2003;36-43
65. Wolf J., Tesch H., Parsa-Parsi R., et al. Current clinical trials for the treatment of adult Hodgkin's disease Common strategies and perspectives. Ann Oncol. 9:(Suppl. 5):1998;S79-S82
66. Connors JM, Reece DE, Diehl V, et al. Hodgkin's lymphoma: New approaches to treatment. In: Hematology 1998, American Society of Hematology, Education Program Book. Washington, DC: American Society of Hematology; 1998. p. 274-295
67. Santoro A., Bonadonna G., Valagussa P., et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 5:1987;27-37
68. Canellos G.P., Anderson J.R., Propert K.J., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 327:1992;1478-1484
69. Canellos G.P., Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med. 346:2002;1417-1418
70. Rueda A., Alba E., Ribelles N., et al. Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma A pilot study. J Clin Oncol. 15:1997;1118-1122
71. Straus D.J., Yahalom J., Zelenetz A.D., et al. Results of a prospective randomized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone vs. ABVD + radiation therapy for early stage non bulky Hodgkin's disease. Blood. 98:2001;769a. [Abstract]
72. Franklin J., Paulus U., Lieberz D., et al. Is the International Prognostic Score for advanced stage Hodgkin's disease applicable in early stage patients? Ann Oncol. 11:2000;617-623
73. Henry-Amar M., Meerwaldt J., Carde P., et al. The EORTC treatment strategy in Hodgkin's lymphoma A 4-decade experience. Leuk Lymphoma. 42:(Suppl. 2):2001;54
74. Sarris A.H., Kliche K.O., Pethambaram P., et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol. 10:1999;433-440
75. Vassilakopoulos T.P., Nadali G., Angelopoulou M.K., et al. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica. 86:2001;274-281
76. Nadali G., Tavecchia L., Zanolin E., et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood. 91:1998;3011-3016
77. Chronowski G.M., Wilder R.B., Tucker S.L., et al. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin's disease. Cancer. 95:2002;2534-2538
78. Rassidakis G.Z., Medeiros L.J., Vassilakopoulos T.P., et al. Bcl-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood. 100:2002;3935-3941
79. Dukers D.F., Meijer C.J.L.M., ten Berge R.L., et al. High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin's disease predict favorable clinical outcome. Blood. 100:2002;36-42
80. Sarris A.H., Kliche K.O., Nadali G., et al. Biologic factors in Hodgkin's disease A window into prognosis and a guide for investigational therapy (Results from the International Hodgkin's Study Group). Leuk Lymphoma. 42:(Suppl. 2):2001;10. [Abstract]
81. Rassidakis GZ, Medeiros LJ, Drakos E, et al. Activated caspase-3 in Hodgkin and Reed-Sternberg cells predicts poorer prognosis in patients with classical Hodgkin's disease treated with ABVD or equivalent regimens [Abstract]. Blood 2002;100
82. Lund M.B., Ihlen H., Voss B.M., et al. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease An echocardiographic study. Heart. 75:1996;591-595
83. Hancock S.L., Tucker M.A., Hoppe R.T. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 85:1993;25-31
84. Valagussa P., Santoro A., Fossati-Bellani F., et al. Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. Blood. 59:1982;488-494
85. van Leeuwen F.E., Chorus A.M.J., van den Belt-Dusebout A.W., et al. Leukemia risk following Hodgkin's disease Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol. 12:1994;1063-1073
86. Pedersen-Bjergaard J., Olesen Larsen S., Struck J., et al. Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet. 11:1987;83-88
87. Kaldor J.M., Day N.E., Clarke A., et al. Leukemia following Hodgkin's disease. N Engl J Med. 322:1990;7-13
88. Swerdlow A.J., Barber J.A., Horwich A., et al. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. Br J Cancer. 75:1997;116-123
89. Rueffer U., Josting A., Franklin J., et al. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group Incidence, treatment, and prognosis. J Clin Oncol. 19:2001;2026-2032
90. Aisenberg A.C., Finkelstein D.M., Doppke K.P., et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer. 79:1997;1203-1210
91. Yahalom J., Petrek J.A., Biddinger P.W., et al. Breast cancer in patients irradiated for Hodgkin's disease A clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol. 10:1992;1674-1681
92. Doria R., Holford T., Farber L.R., et al. Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol. 13:1995;2016-2022